Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × tivozanib × Clear all

Phase

Phase 2 5 Phase NA 1 Phase 1/2 1

Status

Completed 3 Withdrawn 1 Terminated 1 Suspended 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 74 Carboplatin 59 Cyclophosphamide 56 Nivolumab 50 Paclitaxel 47 Gemcitabine 43 Cisplatin 43 Dexamethasone 40 Radiotherapy 35 Rituximab 31 Capecitabine 30 Docetaxel 28 Bevacizumab 28 fludarabine 26 atezolizumab 25 avelumab 24 Cytarabine 24 Lenalidomide 23 Cetuximab 23 Trastuzumab 22 Oxaliplatin 22 Fluorouracil 22 Azacitidine 22 venetoclax 21 Temozolomide 21 Ipilimumab 21 130-nm albumin-bound paclitaxel 21 Filgrastim 20 Bortezomib 20 Albumin-Bound Paclitaxel 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡